Regulation of myeloid leukocyte mediated immunity

Across TCGA pan-cancer cohorts, RNA activity of the Regulation of myeloid leukocyte mediated immunity pathway differs between tumor and matched normal tissue in 9 of the 18 cancer types tested.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where pathway activity is higher in tumor tissue than in matched normal tissue. In most cancer types, this pathway shows higher activity in tumors, although a few cancer types, such as LUSC and LUAD, show the opposite pattern, with lower activity in tumor tissue.

KIRC, LUSC, and HNSC show the most reproducible tumor–normal differences in pathway activity.

Tumor vs normal pathway activity by lineage

Ranked by sampling consensus. Activity change represents the tumor-versus-normal difference in pathway activity on a log₂ scale. Positive values indicate higher pathway activity in tumor tissue. The reported p-values are derived from the corresponding differential activity tests.

Lineage	Gender	Stage	Activity change	p	Sampling consensus
KIRC	Female	II,III,IV	+0.055	<.001	12	view →
LUSC	Female	All	−0.071	<.001	8	view →
HNSC	Female	II,III,IV	+0.035	.001	8	view →
LUAD	Female	All	−0.032	<.001	8	view →
COAD	All	III,IV	−0.029	<.001	8	view →
STAD	All	All	+0.034	.002	6	view →
LIHC	Male	All	−0.029	<.001	6	view →
KIRP	All	All	+0.033	.002	2	view →
CHOL	All	All	+0.033	.026	1	view →

Pink = more active in tumor, green = less active in tumor. Showing the 9 strongest of 9 lineages.

GO:0002886–KIRC

Open the KIRC breakdown →